Skip to Content
Discovering the causes of cancer and the means of prevention

Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines—The ESCUDDO* Study

Certain types of human papillomavirus (HPV) cause almost all cases of cervical cancer, as well as cancers at other anatomic sites in men and women. Vaccines that protect against HPV can substantially reduce the risk of cervical cancer, and other cancers attributable to HPV infection. However, HPV vaccination rates are too low, especially in countries with very high rates of cervical cancer and low resources. These vaccines are expensive—many countries cannot afford them—more than one dose is needed, and giving multiple doses can be difficult, especially in low resource settings. Researchers are conducting a new study in order to determine if one dose of the HPV vaccines works as well as giving two doses of these vaccines to young women.

Potential Public Health Impact

If one dose of an HPV vaccine were found to be sufficient to reduce cervical cancer burden, we would expect more widespread vaccine uptake in the United States, and around the world, with vaccination programs being able to operate at an overall lower cost.

Additionally, findings from the trial may make it possible for future evaluations of one-dose HPV vaccination to be smaller-scale immunogenicity trials, rather than efficacy trials, which could expedite expansion to other populations, ages, and vaccine formulations.

Finally, these findings could transform the current vaccine development paradigm by providing the first example of a single-dose subunit vaccine that induces durable protective immunity.

Study Design

There are two components to the study: (1) a controlled, randomized, double-blinded non-inferiority clinical trial to compare one-dose to two-dose vaccination; and (2) a concurrent epidemiologic survey for HPV infection status among unvaccinated women.

The trial will enroll 20,000 girls 12 to 16 years old residing in Costa Rica. Participants will be randomized in two stages to one of four arms (one dose of the bivalent vaccine, two doses of the bivalent vaccine, one dose of the nonavalent vaccine and two doses of the nonavalent vaccine); the first randomization at enrollment will assign participants to one of the two study vaccines and at the second visit they will be randomized to one or two doses. Girls randomized to the one dose arm will receive an active control (i.e. Tdap) at the time of the second vaccine dose. After vaccination, girls will be followed every six months for four years to assess the presence of persistent cervical HPV infections and antibody titers, by dose group and vaccine type. In the U.S., Cervarix® and GARDASIL®9 are currently approved for two doses in younger recipients and three doses in older recipients. 

The epidemiologic HPV survey will enroll a group of unvaccinated females from the same geographic areas; they will range in age from 17 to 20. These females will attend two study visits six months apart to determine their HPV DNA status; there will be no additional follow-up. These females will be offered HPV vaccination at the enrollment and six-month study visits.

At each visit, participants will fill out a questionnaire and give a urine sample. They may give blood samples. The older participants will use a swab to collect cells from their cervix and vagina.

Study Rationale and Background

The impetus for this trial stemmed from the NCI Costa Rica Vaccine Trial, a phase-III efficacy trial that launched in 2004; in post-hoc analyses, investigators from that trial reported that one or two doses may be efficacious and that antibody titers remained elevated for years after a single vaccine dose. The latter finding was particularly novel and unexpected, given that previous subunit vaccines have typically required more than one dose (prime/boost regimen) to induce lasting responses.

* ESCUDDO (“Estudio de Comparacion de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano (VPH)”) is a scientific evaluation of one or two doses of vaccine against human papillomavirus.

Clinical trials identifier: NCT03180034

ESCUDDO is co-funded by the NCI and the Bill & Melinda Gates Foundation, with support from the International Agency for Research on Cancer. 

For more information, contact Dr. Aimée Kreimer.
Infections and Immunoepidemiology Branch - Research Areas